Research programme: antimalarials - PLIVA/WRAIRAlternative Names: Antimalarials research programme - PLIVA/WRAIR; Azithromycin analogues research programme - PLIVA/WRAIR; Research programme: antimalarials - Pliva Research Institute/WRAIR
Latest Information Update: 16 Aug 2007
At a glance
- Originator PLIVA Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 05 May 2006 GlaxoSmithKline aquires the research arm of PLIVA
- 20 Jul 2005 Preclinical trials in Malaria in USA (unspecified route)